| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2137165 | Leukemia Research | 2012 | 7 Pages |
Abstract
CCAAT/enhancer binding protein alpha (C/EBPα) induction induces monocytic differentiation even in acute myeloid leukaemia (AML). In this study, the induction/activation of C/EBPα in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor. Combining these agents increased PU.1, C/EBPɛ and C/EBPα expression, increased the p42/p30 C/EBPα ratio, and decreased C/EBPα phosphorylation at serine 21, and was accompanied by growth inhibition, induction of CD11b expression and apoptosis in AML cell lines. Thus, agents that induce sufficient levels of C/EBPα expression might be useful in treating AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hideki Yoshida, Toshihiko Imamura, Atsushi Fujiki, Yoshifumi Hirashima, Mitsuru Miyachi, Takeshi Inukai, Hajime Hosoi,